Test Price
2,800 AED✅ Home Collection Available
LTBP2 Gene Weill-Marchesani Syndrome Type 3 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance by DHA-Licensed Genetic Counselors.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
- Regulatory Compliance: Adherence to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
This Next-Generation Sequencing (NGS) test delivers 99.9% sensitivity for detecting LTBP2 mutations associated with Weill-Marchesani syndrome type 3, critical for early pediatric intervention. The assay targets the full coding region and splice-site boundaries, validated against enhanced genomic reference databases. Results guide pediatric ophthalmology, cardiology, and orthopedic management, and facilitate cascade family screening.
| Aspect | Our Test (UAE Reference Lab) | Closest Alternative (Sanger only) |
|---|---|---|
| Precision | NGS + Confirmatory Sanger Sequencing | Sanger Sequencing only (lower sensitivity for mosaicism) |
| Method / Platform | Illumina NovaSeq X Plus with bioinformatic pathogenicity scoring | Capillary electrophoresis, single-gene analysis |
| Turnaround Time | 3 – 4 Weeks | 4 – 6 Weeks |
Physician Insight & Safety Protocols
“As a consultant in medical genetics, I recognize that pursuing genetic testing for a family member or yourself can be an emotionally complex decision. This LTBP2 gene analysis provides definitive diagnostic clarity, yet results must always be assessed within the full context of clinical presentation and family pedigree. Our multidisciplinary team is committed to guiding you through every stage of this diagnostic process.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics — DHA Registration ID: 9294403
⚠️ Medication Advisory
Do not discontinue or alter any prescribed medication without prior consultation with your treating physician.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Pregnancy requires obstetric clearance; severe hemophilia; inability to provide informed consent (guardian required for minors as per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Emergency Red Flags: If you experience severe anxiety, suicidal ideation, or new-onset symptoms demanding immediate medical attention, discontinue the test process and visit the nearest Emergency Department.
Patient FAQ & Clinical Guidance
1. What is the LTBP2 gene test for Weill-Marchesani syndrome type 3?
Answer: The LTBP2 genetic test precisely detects disease-causing variants linked to Weill-Marchesani syndrome type 3 for rapid, accurate diagnosis. This NGS assay screens the entire LTBP2 coding sequence, enabling identification of both known and novel mutations. Results guide pediatric ophthalmology, cardiology, and orthopedic management, and facilitate cascade family screening.
2. How is the sample collected for LTBP2 gene testing?
Answer: Sample collection is performed via a simple, painless blood draw or fingertip blood spot on an FTA card for convenience. Our DHA-licensed phlebotomists arrive at your home within a scheduled window; the sample is immediately placed in ISO-certified cold-chain transport to the sequencing facility. VIP Mobile Phlebotomy is available daily from 8 AM to 11 PM.
3. Is genetic counseling included before the test?
Answer: Yes, a mandatory pre-test genetic counseling session is provided to fully explain risks, benefits, and family implications. This session, conducted by a DHA-certified counselor, includes pedigree drawing, discussion of inheritance patterns, and psychosocial support; it is a prerequisite under Federal Decree-Law No. 4 of 2016 on Medical Liability and aligns with best clinical practice standards.
4. What is the turnaround time for results?
Answer: The standard turnaround time is 3 to 4 weeks from sample receipt at the laboratory. This accounts for comprehensive NGS sequencing, bioinformatic analysis, variant interpretation, and confirmatory Sanger validation where indicated.
5. How should I prepare for the blood collection?
Answer: No special preparation such as fasting is required for this genetic test. Stay hydrated and inform the phlebotomist of any bleeding disorders or anticoagulant medications during the appointment scheduling.
UAE Regulatory & Data Privacy Adherence
This diagnostic service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed exclusively within UAE jurisdiction. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | LTBP2 Gene Sequencing – Weill-Marchesani Syndrome Type 3 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Peripheral whole blood or FTA card blood spot |
| Methodology Used | Next-Generation Sequencing (NGS) with confirmatory Sanger sequencing |
| ICD-10-CM Code | Q87.1 |
| LOINC Code | 21636-6 |
| DHA Facility License & Address | License No: 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians